Item 5.02 Departure of Directors or Principal Officers Election of Directors Appointment of Principal Officers.On January 15 2024 Chief Commercial Officer James Wilbur and 10x Genomics Inc. (the Company) entered into a Transition and Separation Agreement (the Agreement) pursuant to which Dr. Wilbur will depart the Company on February 1 2024. Dr. Wilbur's departure is not due to any disagreement with the Companys management team operations financial statements policies or procedures.Pursuant to the Agreement Dr. Wilbur will be awarded a one time severance payment of an amount equal to six months of his base salary and a one time COBRA-related payment of $14335. Dr. Wilbur will not receive an annual performance bonus for the full year 2023. Such payments and benefits are conditioned upon Dr. Wilbur continuing to comply with certain obligations applicable to him and upon execution and termination delivery and non-revocation of a general release of claims.The above description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement which the Company expects to file as an exhibit to its Annual Report on Form 10-K for the year ended December 31 2023.SignaturesPursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.10x Genomics Inc.By/s/ Eric S. WhitakerNameEric S. WhitakerTitleChief Legal Officer